Is a cure for Parkinson's disease hiding inside us?

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Alpha-synuclein (a-syn) oligomers and fibrils are key drivers of neurodegeneration in Parkinson's disease (PD).
• Current therapeutic strategies targeting these species remain challenging.
• Amphipathic, cationic helical peptides show potential by inhibiting a-syn aggregation and neurotoxicity.

Purpose of the Study:

• To investigate the potential of endogenous peptides, specifically LL-37, as a novel therapeutic strategy for Parkinson's disease.
• To determine if LL-37 can inhibit alpha-synuclein (a-syn) oligomer and fibril formation.
• To assess the neuroprotective effects of LL-37 against a-syn-induced toxicity.

Main Methods:

• In vitro studies examining the interaction of LL-37 with alpha-synuclein (a-syn) species.
• Amyloid formation assays to quantify the effect of LL-37 on a-syn aggregation.
• Cell-based assays to evaluate neurotoxicity and neuroprotection.

Main Results:

• LL-37 selectively binds to soluble toxic species of alpha-synuclein (a-syn).
• LL-37 inhibits the formation of a-syn amyloid fibrils.
• LL-37 demonstrates neuroprotective effects against a-syn-induced toxicity in cellular models.

Conclusions:

• Endogenous peptides like LL-37 represent a promising new therapeutic avenue for Parkinson's disease.
• LL-37's ability to target toxic a-syn species offers a potential mechanism for disease modification.
• Further research into LL-37 and similar peptides could lead to novel PD treatments.